SCHEMBL454299

SCHEMBL454299

CC(C)OC(=O)C(C)(C)Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 3/20 0.39
ADRA1A P35348 2/20 0.39
USP2 O75604 1/20 0.39
ABCB11 O95342 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
ADRB3 P13945 1/20 0.39
HPGD P15428 1/20 0.39
CNR1 P21554 1/20 0.39
ACHE P22303 1/20 0.39
SLC6A2 P23975 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5824309 0.84 TSHR (0.43) TSHRMEN1KMT2ALMNAADRA1A
SCHEMBL17191649 0.84 TSHR (0.32) TSHRMEN1KMT2AMAPT
SCHEMBL15685105 0.84 TSHR (0.32) TSHRMEN1KMT2AMAPT
SCHEMBL9901276 0.84 TSHR (0.32) TSHRMEN1KMT2A
SCHEMBL1254813 0.82 ELANE (0.31) TSHR
SCHEMBL9678131 0.81 TSHR (0.46) TSHRMEN1KMT2ALMNAADRA1A
SCHEMBL28890230 0.81 TSHR (0.46) TSHRMEN1KMT2ALMNAADRA1A
SCHEMBL25258063 0.80 MEN1 (0.32) TSHRMEN1KMT2ALMNAADRA1A
SCHEMBL20561810 0.80
SCHEMBL6063978 0.78 TSHR (0.48) TSHRMEN1KMT2ALMNAADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206723-A1 METHODS AND PROCESSES FOR THE PREPARATION OF MCT4 INHIBITORS Vettore, LLC 2025-06-26 US claimed
EP-4568953-A1 METHODS AND PROCESSES FOR THE PREPARATION OF MCT4 INHIBITORS Vettore, LLC (US) 2025-06-18 EP claimed
CN-119894883-A Methods and processes for preparing MCT4 inhibitors 维托尔股份有限公司 2025-04-25 CN claimed
CN-118813080-A Metal-based anticorrosive paint and preparation method and application thereof 国科先材(合肥)科技有限公司 2024-10-22 CN claimed
WO-2024031445-A1 METHODS AND PROCESSES FOR THE PREPARATION OF MCT4 INHIBITORS Vettore, LLC (US) 2024-02-15 WO claimed
CN-116622039-B Vinyl pyrrolidone segmented copolymer and preparation method and application thereof 上海宇昂水性新材料科技股份有限公司 2023-10-24 CN claimed
CN-116589636-B Silver nanowire end capping agent and preparation method and application thereof 上海宇昂水性新材料科技股份有限公司 2023-09-22 CN claimed
CN-116589636-A Silver nanowire end capping agent and preparation method and application thereof 上海宇昂水性新材料科技股份有限公司 2023-08-15 CN claimed
CN-116554014-A Preparation method of fenofibrate and impurities thereof 浙江恒康药业股份有限公司 2023-08-08 CN claimed
CN-116082145-A Fibrate derivative with antioxidant activity, synthesis method and application thereof 天津科技大学 2023-05-09 CN claimed
CN-113185469-B Method for modifying photoregulated diaryl dihydrophenazine 南京先进生物材料与过程装备研究院有限公司 2022-08-09 CN claimed
CN-113185469-A Method for modifying photoregulated diaryl dihydrophenazine 南京先进生物材料与过程装备研究院有限公司 2021-07-30 CN claimed
EP-0582441-A1 Processes for the preparation of tyramine derivatives CHEMAGIS LTD. (IL) 1994-02-09 EP claimed
CN-116554014-B Preparation method of fenofibrate and impurities thereof 浙江恒康药业股份有限公司 2025-12-23 CN disclosed
US-20250206723-A1 METHODS AND PROCESSES FOR THE PREPARATION OF MCT4 INHIBITORS Vettore, LLC 2025-06-26 US disclosed
EP-4568667-A2 SALTS OF HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTER 4 FOR THE TREATMENT OF DISEASE Vettore, LLC (US) 2025-06-18 EP disclosed
WO-2005039596-A1 SILYL PHENOLS FOR PROMOTING VASCULAR HEALTH AMYLIN PHARMACEUTICALS, INC. (US) 2005-05-06 WO disclosed
US-20040073058-A1 Process for the preparation of fibrates OLON S.P.A. (IT) 2004-04-15 US disclosed
EP-0582441-A1 Processes for the preparation of tyramine derivatives CHEMAGIS LTD. (IL) 1994-02-09 EP disclosed
US-4739101-A Method for the preparation of fibrates FOURNIER INNOVATION ET SYNERGIE (FR) 1988-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040073058-A1 Process for the preparation of fibrates CPT1A, CES1, CPT1B TSHR 1616/4885MEN1 4105/4885KMT2A 2168/4885
US-20250206723-A1 METHODS AND PROCESSES FOR THE PREPARATION OF MCT4 INHIBITORS SLC16A3, SLC16A1, SLC16A8 TSHR 2573/4885MEN1 524/4885KMT2A 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.